Critical Survey: Maplebear (NASDAQ:CART) & OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRXGet Free Report) and Maplebear (NASDAQ:CARTGet Free Report) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares OptimizeRx and Maplebear’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OptimizeRx -27.41% -4.92% -3.41%
Maplebear 13.37% 13.78% 10.51%

Volatility & Risk

OptimizeRx has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Maplebear has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for OptimizeRx and Maplebear, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OptimizeRx 0 2 6 0 2.75
Maplebear 0 13 13 0 2.50

OptimizeRx currently has a consensus price target of $9.71, suggesting a potential upside of 97.85%. Maplebear has a consensus price target of $47.14, suggesting a potential upside of 12.18%. Given OptimizeRx’s stronger consensus rating and higher probable upside, research analysts clearly believe OptimizeRx is more favorable than Maplebear.

Institutional & Insider Ownership

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 63.1% of Maplebear shares are held by institutional investors. 6.1% of OptimizeRx shares are held by company insiders. Comparatively, 36.0% of Maplebear shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares OptimizeRx and Maplebear”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OptimizeRx $88.18 million 1.03 -$17.57 million ($1.33) -3.69
Maplebear $3.30 billion 3.27 -$1.62 billion $1.49 28.20

OptimizeRx has higher earnings, but lower revenue than Maplebear. OptimizeRx is trading at a lower price-to-earnings ratio than Maplebear, indicating that it is currently the more affordable of the two stocks.

Summary

Maplebear beats OptimizeRx on 9 of the 14 factors compared between the two stocks.

About OptimizeRx

(Get Free Report)

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About Maplebear

(Get Free Report)

Maplebear Inc., doing business as Instacart, engages in the provision of online grocery shopping services to households in North America. It sells and delivers grocery products, as well as pickup services through a mobile application and website. It also operates virtual convenience stores; and provides software-as-a-service solutions to retailers. The company was incorporated in 2012 and is based in San Francisco, California.

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.